Cerebrolysin

Cerebrolysin is a preparation derived from porcine brain tissue through an enzymatic process. The resulting substance is a mixture composed of low molecular weight peptides (up to 10 kDa) and free amino acids.

The name Cerebrolysin is also used for a pharmaceutical drug product manufactured by EVER Neuro Pharma, which has been studied and is available in some countries. The material sold here is intended solely for laboratory research purposes and is not the approved pharmaceutical drug.

Neurotrophic Concept

The study of this material is related to the neurotrophic hypothesis, which posits that brain-derived growth factors are involved in neuronal maintenance, differentiation, and synaptic plasticity. This preparation contains a complex mixture of peptides and amino acids.

The peptide fraction contains fragments with structural similarities to neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). It is hypothesized that these components may interact with multiple neurotrophin receptor systems.

In various experimental models, Cerebrolysin has been observed to influence multiple cellular pathways relevant to neuronal function.

Neurotrophic Signaling

In vitro studies suggest the peptide mixture can activate neurotrophin receptor signaling pathways, such as TrkA and TrkB receptors. Activation of these receptors is linked to intracellular cascades including the PI3K/Akt and MAPK/ERK pathways, which are involved in cell signaling related to cell survival and plasticity.

Anti-Apoptotic Effects

In some cellular models of stress, Cerebrolysin has been reported to modulate markers associated with apoptosis. These observations include changes in the expression of Bcl-2 family proteins, caspase activity, and mitochondrial membrane integrity.

Synaptic Plasticity

Research has examined the effects of this peptide mixture on synaptic structure and function. Studies in neuronal cultures have reported observations of altered dendritic branching and spine density. Effects on long-term potentiation (LTP) have also been investigated in electrophysiological studies.

Neuroinflammation Modulation

In cell culture and animal models of neuroinflammation, Cerebrolysin has been observed to modulate microglial activation and the production of cytokines such as IL-1β, IL-6, and TNF-α.

Metabolic Influence

The material has been studied for its influence on neuronal energy metabolism, with research investigating its effects on glucose utilization and mitochondrial function in the context of experimental models of ischemia and hypoxia.

The branded pharmaceutical Cerebrolysin has been investigated in numerous preclinical and clinical studies.

Stroke Research

Clinical trials have evaluated the effects of the branded drug Cerebrolysin in the context of acute ischemic stroke. A Cochrane systematic review analyzed data from several randomized controlled trials investigating its use. The CASTA trial (Cerebrolysin Acute Stroke Treatment in Asia), which enrolled over 1,000 subjects, investigated functional outcomes, though its primary endpoint was not met.

In preclinical animal models of cerebral ischemia, administration of Cerebrolysin has been associated with a reduction in infarct volume and has been studied for its effects on angiogenesis and neurogenesis in damaged brain regions.

Traumatic Brain Injury (TBI)

The pharmaceutical product has been studied in human subjects with traumatic brain injury to assess effects on cognitive function. In animal models of TBI, research has investigated its effects on brain edema, blood-brain barrier integrity, and markers of neuroinflammation.

Alzheimer's Disease and Dementia

Clinical trials have investigated the effects of Cerebrolysin on cognitive function in subjects with Alzheimer's disease. A meta-analysis of such trials reported on its effects on cognitive measures compared to placebo. The material's interaction with neurotrophic pathways like BDNF signaling provides a rationale for this area of research.

Other Areas of Study

The branded drug has also been a subject of research in studies related to vascular dementia, diabetic neuropathy, and Parkinson's disease models.

This material is sold for in vitro and laboratory research use only. It is not intended for human or veterinary use. This product is derived from porcine tissue and should be handled accordingly in a laboratory setting. It has been noted that this peptide solution should not be mixed with balanced amino acid solutions due to potential chemical incompatibilities. For full safety and handling information, please refer to the Safety Data Sheet (SDS).